These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11493473)

  • 21. Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs.
    Elias F; Flo J; Lopez RA; Zorzopulos J; Montaner A; Rodriguez JM
    J Immunol; 2003 Oct; 171(7):3697-704. PubMed ID: 14500668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
    Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
    J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
    Roda JM; Parihar R; Carson WE
    J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor.
    Yuan S; Qiao T; Chen W
    Cancer Biother Radiopharm; 2011 Apr; 26(2):203-8. PubMed ID: 21539452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease.
    Alpdogan O; Schmaltz C; Muriglan SJ; Kappel BJ; Perales MA; Rotolo JA; Halm JA; Rich BE; van den Brink MR
    Blood; 2001 Oct; 98(7):2256-65. PubMed ID: 11568014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.
    Kawarada Y; Ganss R; Garbi N; Sacher T; Arnold B; Hämmerling GJ
    J Immunol; 2001 Nov; 167(9):5247-53. PubMed ID: 11673539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic intrabone marrow-bone marrow transplantation plus donor lymphocyte infusion suppresses growth of colon cancer cells implanted in skin and liver of rats.
    Koike Y; Adachi Y; Suzuki Y; Iwasaki M; Koike-Kiriyama N; Minamino K; Nakano K; Mukaide H; Shigematsu A; Kiyozuka Y; Tubura A; Kamiyama Y; Ikehara S
    Stem Cells; 2007 Feb; 25(2):385-91. PubMed ID: 17284650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo.
    Schlaepfer E; Audigé A; von Beust B; Manolova V; Weber M; Joller H; Bachmann MF; Kundig TM; Speck RF
    J Virol; 2004 Nov; 78(22):12344-54. PubMed ID: 15507621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects.
    Brown L; Roda J; Terrell C; Chaudhury AR; Crespin T; Carson WE; Lesinski GB
    Surgery; 2006 Aug; 140(2):297-306. PubMed ID: 16904983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT.
    Liu L; Chang YJ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1350-1359. PubMed ID: 29649617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-asialo GM1 antiserum treatment of lethally irradiated recipients before bone marrow transplantation: evidence that recipient natural killer depletion enhances survival, engraftment, and hematopoietic recovery.
    Tiberghien P; Longo DL; Wine JW; Alvord WG; Reynolds CW
    Blood; 1990 Oct; 76(7):1419-30. PubMed ID: 2207317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.
    Sehn LH; Alyea EP; Weller E; Canning C; Lee S; Ritz J; Antin JH; Soiffer RJ
    J Clin Oncol; 1999 Feb; 17(2):561-8. PubMed ID: 10080600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
    Davila E; Celis E
    J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia.
    Lowdell MW; Craston R; Ray N; Koh M; Galatowicz G; Prentice HG
    Bone Marrow Transplant; 1998 Apr; 21(7):679-86. PubMed ID: 9578307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides.
    Fujii H; Trudeau JD; Teachey DT; Fish JD; Grupp SA; Schultz KR; Reid GS
    Blood; 2007 Mar; 109(5):2008-13. PubMed ID: 17068155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antitumor effect of CpG oligonucleotides on human neuroblastoma xenografts in nude mice].
    Yao QH; Tang YJ; Gao FH; Tang JY
    Ai Zheng; 2009 Apr; 28(4):344-9. PubMed ID: 19622291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.